A5081468120- Glioma Diagnosis and Treatment
- Melanoma and MAPK Pathways
- Cancer Immunotherapy and Biomarkers
- Brain Metastases and Treatment
- Cutaneous Melanoma Detection and Management
- CAR-T cell therapy research
- Cancer-related cognitive impairment studies
- Immunotherapy and Immune Responses
- Air Quality and Health Impacts
- Cancer, Stress, Anesthesia, and Immune Response
- Synthesis and biological activity
- Asthma and respiratory diseases
- Protein Degradation and Inhibitors
- Cancer Genomics and Diagnostics
- Radiopharmaceutical Chemistry and Applications
- Brain Tumor Detection and Classification
- Cardiac tumors and thrombi
- Autoimmune and Inflammatory Disorders Research
- Neuroblastoma Research and Treatments
- Radiomics and Machine Learning in Medical Imaging
- Immune cells in cancer
- Lung Cancer Research Studies
- Computational Drug Discovery Methods
- Lymphadenopathy Diagnosis and Analysis
- Synthesis of Tetrazole Derivatives
Mathys (Netherlands)
2024
Universitair Ziekenhuis Brussel
2022-2024
Molecular Oncology (United States)
2024
Vrije Universiteit Brussel
2022-2024
Ghent University Hospital
2022-2023
GTx (United States)
2023
Patients with advanced melanoma who progress after treatment immune checkpoint-inhibitors (ICI) and BRAF-/MEK-inhibitors (if BRAF V600 mutated) have no remaining effective options. The presence of CD1c (BDCA-1)+ CD141 (BDCA-3)+ myeloid dendritic cells (myDC) in the tumor microenvironment correlates pre-existing recognition responsiveness to checkpoint blockade. synthetic saponin-based adjuvant AS01B enhances adaptive immunity through involvement myDC. In this first-in-human phase I clinical...
Patients with
Abstract Background Recurrent high-grade glioma (rHGG) lacks effective life-prolonging treatments and the efficacy of systemic PD-1 CTLA-4 immune checkpoint inhibitors is limited. The multi-cohort Glitipni phase I trial investigates safety feasibility intraoperative intracerebral (iCer) postoperative intracavitary (iCav) nivolumab (NIVO) ± ipilimumab (IPI) treatment following maximal safe resection (MSR) in rHGG. Materials methods Patients received 10 mg IV NIVO within 24 h before surgery,...
Focal radiation necrosis of the brain (fRNB) is a late adverse event that can occur following treatment benign or malignant lesions with stereotactic therapy (SRT) radiosurgery (SRS). Recent studies have shown incidence fRNB higher in cancer patients who received immune checkpoint inhibitors. The use bevacizumab (BEV), monoclonal antibody targets vascular endothelial growth factor (VEGF), an effective for when given at dose 5–7.5 mg/kg every two weeks. In this single-center retrospective...
Melanoma patients failing all approved treatment options have a poor prognosis. The antimelanoma activity of regorafenib (REGO), multitargeted kinase inhibitor, has not been investigated in this patient population. objective response rate and safety REGO advanced melanoma was retrospectively. Twenty-seven received treatment. All had progressed on anti–programmed cell death protein 1 (PD-1) anti–cytotoxic T-lymphocyte–associated 4 (CTLA-4) checkpoint inhibition BRAF/MEK inhibitors (in case...
Clonal MAPK-pathway activating mutations in the
Experimental studies suggest that neutrophils could contribute to allergic asthma pathogenesis, is mainly driven by type 2 immunity. Inhalation of diesel exhaust particles (DEP) implicated in both exacerbation and development asthma. Since exposure DEP associated with a neutrophilic component, we aimed investigate how the combination allergens modulates responses. Human bronchial epithelial cells (HBEC) were exposed house dust mite (HDM), or HDM + vitro determine expression...
<b><i>Introduction:</i></b> Pleiomorphic xanthoastrocytoma (PXA) is considered a low-grade glioma with favorable prognosis following surgical resection. We present case report of <i>BRAF</i><sup><i>V600E</i></sup> mutant malignantly transformed and disseminated PXA that was successfully treated BRAF-/MEK-targeted therapy (dabrafenib/trametinib). <b><i>Case Presentation:</i></b> At the age 16 years, our...
There is a need for better understanding of survivorship-related issues in advanced cancer survivors treated with immune checkpoint blockade (ICB). The purpose this study was to identify issues, focus on psychological distress, cognitive complaints, physical sequelae, impact family dynamics, and care needs unresectable, ICB. Semi-structured interviews patient-reported outcome measures (PROMs) were conducted followed up at the University Hospital Brussels. We performed content analysis...
There are no active treatment options for patients with progressive melanoma brain metastases (MBM) failing immune checkpoint blockade (ICB) and BRAF/MEK inhibitors (BRAF/MEKi). Regorafenib (REGO), an oral multi-kinase inhibitor (incl. RAF-dimer inhibition), can overcome adaptive resistance to BRAF/MEKi in preclinical models.
Background: Antibodies that inhibit the programmed cell death protein 1 (PD-1) receptor offer a significant survival benefit, potentially cure (i.e., durable disease-free following treatment discontinuation), substantial proportion of patients with advanced melanoma. Most however fail to respond such or acquire resistance. Previously, we reported baseline total metabolic tumour volume (TMTV) determined by whole-body [18F]FDG PET/CT was independently correlated and able predict futility...
Summary The Covid-19 vaccination has been rapidly implemented among patients with cancer. We present two cases of endocrine tumours who developed lymphadenopathy following a vaccination. In the case patient multiple neoplasia (MEN) 1 syndrome, an 18-fluorodeoxyglucose (18FDG)-PET/CT showed positive axillary lymph nodes. Further work-up fine needle aspiration reactive pattern in ipsilateral arm shortly before 18FDG-PET/CT. A second patient, follow-up for thyroid cancer, clinical...
Background and purpose: Primary angiosarcoma of the spleen (PAS), an exceptionally rare aggressive neoplasm with high metastatic risk (70%–85%), is frequently diagnosed in advanced or stage. It presents diagnostic challenges due to its nonspecific symptomatology resemblance benign vascular lesions various imaging modalities. Patients methods: This case series aims clarify difficulties by comparing characteristics (CT-scan, MRI, [18F]FDG-PET/CT) as well pathological findings three PAS cases...
2037 Background: Intracerebral (iCer) administration (admin) of ipilimumab (IPI) and nivolumab (NIVO) plus IV NIVO following resection recurrent high-grade glioma (rHGG) was well tolerated showed encouraging overall survival (OS) (J. Duerinck et al. JITC 2021). The safety additional postoperative (postop) bi-weekly intracavitary (iCav) admin or + IPI (: first in human intracranial CTLA-4 blockade) investigated a phase I trial (3+3 design with cohort expansion). Methods: Within 24h prior to...
9518 Background: A majority of advanced melanoma patients (pts) will eventually progress despite treatment with PD-(L)1/CTLA-4/LAG-3 immune checkpoint- and BRAF-/MEK-inhibitors (BRAF-/MEKi; restricted to BRAF V600 -mutant pts). Retrospective case observations indicate activity regorafenib (REGO) in this setting (1). Methods: This single center, prospective, two-stage, phase 2 clinical trial, investigates REGO 80 mg QD (continuous dosing) pts refractory standard care treatment. Objective...
Abstract Leptomeningeal melanoma metastases (LMM) are associated with poor survival. Diagnosis is based on clinical presentation, brain MRI and cerebrospinal fluid (CSF) analysis. Inconclusive findings at initial presentation can delay treatment. In this single‐center case series, detection of BRAF V600 ‐ NRAS Q61 ‐mutant cell‐free tumor DNA (cfDNA) in CSF was evaluated as a complementary diagnostic biomarker. 12 patients suspicion LMM, retrospective analysis MRI, cytology cfDNA 1 mL using...
Abstract BACKGROUND Intracranial (iCran) administration of the PD-1 and CTLA-4 blocking monoclonal antibodies nivolumab (NIVO) ipilimumab (IPI) at time resection recurrent high-grade glioma (rHGG) is safe resulted in encouraging survival (NCT03233152). CD1c(BDCA-1)+ /CD141(BDCA-3)+ myeloid dendritic cells (myDC) play a pivotal role initiating an adaptive anti-tumor immune response licensing effector within tumor microenvironment. iCran injection autologous myDC pts with rHGG was found to be...